A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Recent advances in the treatment of chronic urticaria have dramatically improved symptom control. However, standard doses of second-generation, histamine type 1 (H1)-receptor antihistamines leave ...

Patients taking low-dose aspirin for its antithrombotic properties can usually continue regular treatment ... test reactions to codeine found in chronic urticaria. The role of avoiding dietary ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a successor have seen some ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Kwatra: Chronic spontaneous urticaria — that's a mouthful ... practitioner when even talking about this disease, let alone treatment options? Kwatra: The number-one thing the patients want ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology ...

Maggie O’Neill is a health writer and reporter based in New York who specializes in covering medical research and emerging wellness trends, with a focus on cancer and addiction. Prior to her ...